• ·	OIPE	
Please type a plus sign (+) inside this box	JUH 0 3 2005	
	E S	•

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	10/612,211				
Filing Date	July 2, 2003				
First Named Inventor	Van Damme				
Group Art Unit	1752				
Examiner Name	Gilliam, Barbara Lee				
Attorney Docket Number	223328				

				U.S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
Un	AA	5,061,591		Nakanishi et al.	Oct. 29, 1991	
		_i				
		·	<u> </u>	···		
			<del> </del>			
	7		<del>                                     </del>			
			<del>-</del>			
		<u> </u>				

FOREIGN PATENT DOCUMENTS									
		F	oreign Patent Docume	nt		•	Trans	slation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No	
R	AB	JP	07-068966	A2	Okamoto Chemical Industry Corp.	Mar. 14, 1955	+		
n	AC	JP	07-089041	A2	Konica Corporation	Apr. 4, 1955	+		
			<u> </u>	ļ					
		l	<u>†</u> .	1		ł		I	

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		slation	
Initials	Initials No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		Yes	No*1
				<del>                                     </del>
		·		

**Examiner Signature Date Considered** 

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).